No Data
AIM Vaccine Gets Marketing Approval From China's NMPA After Phase III Trials Completion
Sino Biopharmaceutical (06660) has obtained the corresponding production license for 13-valent pneumococcal conjugate vaccine, submitted for market registration, and the bottom transaction has hit a historic new high.
According to the Securities Times app, Amy Vaccine (06660) announced that the company's independently developed 13-valent combined pneumonia vaccine has been submitted to the National Pharmaceuticals and Food and Drug Administration...
Express News | AIM Vaccine - Unit Obtained Requisite Drug Production License From Nmpa for Manufacturing 13-Valent Pneumonia Conjugate Vaccine
AIM Vaccine Unit's RSV Drug Approved by NMPA for Clinical Trials
Aimi (6660.HK) mRNA RSV vaccine approved for clinical trials, which domestic enterprise can take the lead in the super billion-dollar track?
Domestic vaccine leader Aimee Vaccine announced on October 30th that the mRNA respiratory syncytial virus (RSV) vaccine developed by the group's holding subsidiary has obtained clinical approval. In the fierce competition for the RSV golden track with a market value of over 10 billion, it has once again attracted high market attention. Among domestic biomedical companies, who can take the lead in this golden RSV track? According to public information, China has not yet approved the listing of any RSV vaccine, while the RSV vaccines of global companies glaxosmithkline and pfizer are already on the market. In 2023, the global sales of RSV vaccines amounted to 2.46 billion US dollars. According to industry consultants at Insight Consulting, it is expected that
Express News | Aim Vaccine’s Heavyweight Single-Product Mrna Rsv Vaccine Obtained the Clinical Trial Approval
AIM Vaccine Insider Ups Holding By 649% During Year
No Data
No Data
